Nature Search

Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis

Italiano and colleagues assess the efficacy and safety of treatment of gastroenteropancreatic neuroendocrine neoplasms with regorafenib plus avelumab and explore biomarkers with resistance prediction value, such as programmed death 1 and indoleamine 2,3-dioxygenase 1 expression and activity.

Sophie Cousin
Jean-Philippe Guégan
Antoine Italiano
Research09 Apr 2025
Nature Cancer

Volume: 6, P: 584-594
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial

Results from the randomized ProfiLER-02 trial, which compared two gene panels in guiding molecular-based treatment in patients with solid tumors, show that a broader gene panel led to more molecular-based recommended therapies compared to a more limited gene panel.

Olivier Trédan
Damien Pouessel
Jean Yves Blay
ResearchOpen Access07 Apr 2025
Nature Medicine

Volume: 31, P: 1502-1508
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer

We describe netrin-1 upregulation in a majority of human endometrial carcinomas and demonstrate that netrin-1 blockade, using the anti-netrin-1 antibody NP137, is effective both in a mouse model and in patients with endometrial carcinomas.

Philippe A. Cassier
Raul Navaridas
Patrick Mehlen
ResearchOpen Access02 Aug 2023
Nature

Volume: 620, P: 409-416
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Results from the precision oncology ARROW trial identify the RET receptor tyrosine kinase as a tissue-agnostic target and the drug pralsetinib’s potential as a well-tolerated treatment option with rapid, robust and durable anti-tumor activity in patients with diverse RET fusion–positive solid tumors.

Vivek Subbiah
Philippe A. Cassier
Giuseppe Curigliano
ResearchOpen Access12 Aug 2022
Nature Medicine

Volume: 28, P: 1640-1645
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial

Marabelle et al. present updated data from the KEYNOTE-158 trial after ~4.5 years of follow-up, reporting an overall response rate of 34% and a median overall survival of 19.8 months in participants with MSI-H/MMR advanced noncolorectal solid tumors.

Aurelien Marabelle
David M. O’Malley
Michele Maio
Research20 Feb 2025
Nature Cancer

Volume: 6, P: 253-258
A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome

Pauline Rochefort
Antoine Italiano
Philippe Alexandre Cassier
ResearchOpen Access20 Dec 2017
Scientific Reports

Volume: 7, P: 1-7
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

Salvagno et al. demonstrated that blocking tumour-associated macrophages in breast cancer enhances the efficacy of chemotherapeutics by promoting intratumoural type I interferon responses.

Camilla Salvagno
Metamia Ciampricotti
Karin E. de Visser
Research18 Mar 2019
Nature Cell Biology

Volume: 21, P: 511-521
Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

Sebastian Bauer
George D. Demetri
Philippe A. Cassier
ResearchOpen Access17 Jun 2021
British Journal of Cancer

Volume: 125, P: 687-698
Correction: Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling

Elodie Roger
Sylvie Martel
Laurent Bartholin
Amendments and CorrectionsOpen Access23 Jan 2020
Cell Death & Disease

Volume: 11, P: 1
SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4

In pancreatic ductal adenocarcinoma cells and patient tissue, SMAD2/3 is shown to mediate oncogenic effects of TGF-β in the absence of SMAD4.

Adrien Bertrand-Chapel
Cassandre Caligaris
Laurent Bartholin
ResearchOpen Access07 Oct 2022
Communications Biology

Volume: 5, P: 1-13
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours

Christophe Le Tourneau
Jean-Pierre Delord
Philippe Alexandre Cassier
ResearchOpen Access25 Aug 2020
British Journal of Cancer

Volume: 123, P: 1481-1489
The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death

Jonathan Vial
Amélie Royet
Marie Castets
Research31 May 2018
Cell Death & Differentiation

Volume: 26, P: 443-454
Generation of a conditional Flpo/FRT mouse model expressing constitutively active TGFβ in fibroblasts

Victoire Cardot-Ruffino
Véronique Chauvet
Laurent Bartholin
ResearchOpen Access03 Mar 2020
Scientific Reports

Volume: 10, P: 1-13
Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling

Elodie Roger
Sylvie Martel
Laurent Bartholin
ResearchOpen Access25 Nov 2019
Cell Death & Disease

Volume: 10, P: 1-19
Autophagy as a therapeutic target in pancreatic cancer

Max Piffoux
Erwan Eriau
Philippe A. Cassier
ReviewsOpen Access15 Sept 2020
British Journal of Cancer

Volume: 124, P: 333-344
Targeting apoptosis in acute myeloid leukaemia

Philippe A Cassier
Marie Castets
Norbert Vey
ReviewsOpen Access24 Aug 2017
British Journal of Cancer

Volume: 117, P: 1089-1098

Search

Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial

Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial

A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

Correction: Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling

SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours

The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death

Generation of a conditional Flpo/FRT mouse model expressing constitutively active TGFβ in fibroblasts

Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling

Autophagy as a therapeutic target in pancreatic cancer

Targeting apoptosis in acute myeloid leukaemia

Search

Quick links

Search

Filter By:

Search

Quick links